Okomera develops an automated organoid screening platform designed to accelerate oncology drug discovery and enable precision oncology. The company plans to commercialize the technology in Europe and the United States with big pharma and life‑science partners. Okomera says the platform will support oncology drug discovery workflows and precision oncology applications and aims to bring the technology to cancer patients. To support its go‑to‑market and scaling efforts it announced a €10.2m fundraise. The company named Resonance as lead investor and cited participation from Berkeley SkyDeck, Polytechnique Ventures and business angels including Irwan Bello and Jacques Lewiner. Early clinical partners mentioned in the announcement include Gustave Roussy and Cancer Research UK Cambridge Institute.

Total raised

$11M

Funding rounds

1

Latest round

Seed

Latest activity

Dec 2023